(ABBV) AbbVie - Overview
Stock: Immunology, Oncology, Neuroscience, Eye Care, Hepatology
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 3.34% |
| Yield on Cost 5y | 7.54% |
| Yield CAGR 5y | 5.98% |
| Payout Consistency | 100.0% |
| Payout Ratio | 66.5% |
| Risk 5d forecast | |
|---|---|
| Volatility | 27.5% |
| Relative Tail Risk | -12.5% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.66 |
| Alpha | 11.24 |
| Character TTM | |
|---|---|
| Beta | 0.441 |
| Beta Downside | 0.586 |
| Drawdowns 3y | |
|---|---|
| Max DD | 20.74% |
| CAGR/Max DD | 0.87 |
Description: ABBV AbbVie January 28, 2026
AbbVie Inc. (NYSE: ABBV) is a research-driven biopharmaceutical firm that develops, manufactures, and markets a broad portfolio of specialty medicines across immunology, oncology, neuroscience, eye care, virology, and gastroenterology. Its flagship products include Humira (autoimmune diseases), Skyrizi and Rinvoq (inflammatory conditions), Imbruvica and Venclexta (hematologic cancers), and a suite of neuroscience and ophthalmology therapies such as Vraylar, Ubrelvy, and Ozurdex. The company also leverages non-prescription assets in facial injectables, regenerative medicine, and body-contouring, and maintains a strategic partnership with OSE Immunotherapeutics.
Key recent metrics (FY 2025, as reported in AbbVie’s Q4 2025 earnings release):
• Total revenue ≈ $58 billion, up 4% YoY, driven by growth in oncology and neuroscience despite a 30% YoY decline in Humira sales to $2.1 billion as biosimilar competition intensifies.
• Research & development expense ≈ $7.5 billion (13% of revenue), reflecting accelerated investment in next-generation immunology and oncology pipelines, including the anticipated Q3 2026 launch of Skyrizi for ulcerative colitis.
• Free cash flow ≈ $12 billion, supporting a 5% dividend yield and a share-repurchase program.
Sector context: the global biologics market is projected to expand at a CAGR of ~10% through 2029, propelled by an aging population and increasing prevalence of chronic inflammatory diseases, which underpins AbbVie’s long-term demand outlook.
For a deeper, data-driven assessment of AbbVie’s valuation dynamics, you may find ValueRay’s analytical tools worth exploring.
Piotroski VR‑10 (Strict, 0-10) 5.0
| Net Income: 4.23b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.10 > 0.02 and ΔFCF/TA -2.88 > 1.0 |
| NWC/Revenue: -17.74% < 20% (prev -23.37%; Δ 5.63% < -1%) |
| CFO/TA 0.10 > 3% & CFO 13.81b > Net Income 4.23b |
| Net Debt (68.74b) to EBITDA (28.29b): 2.43 < 3 |
| Current Ratio: 0.72 > 1.5 & < 3 |
| Outstanding Shares: last quarter (1.77b) vs 12m ago 0.06% < -2% |
| Gross Margin: 73.34% > 18% (prev 0.70%; Δ 7264 % > 0.5%) |
| Asset Turnover: 45.46% > 50% (prev 41.68%; Δ 3.78% > 0%) |
| Interest Coverage Ratio: 3.33 > 6 (EBITDA TTM 28.29b / Interest Expense TTM 2.83b) |
Altman Z'' -0.41
| A: -0.08 (Total Current Assets 28.54b - Total Current Liabilities 39.39b) / Total Assets 133.90b |
| B: -0.11 (Retained Earnings -14.23b / Total Assets 133.90b) |
| C: 0.07 (EBIT TTM 9.43b / Avg Total Assets 134.53b) |
| D: 0.0 (Book Value of Equity 0.0 / Total Liabilities 136.50b) |
| Altman-Z'' Score: -0.41 = B |
What is the price of ABBV shares?
Over the past week, the price has changed by +0.19%, over one month by +0.58%, over three months by +2.82% and over the past year by +19.67%.
Is ABBV a buy, sell or hold?
- StrongBuy: 12
- Buy: 4
- Hold: 12
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the ABBV price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 244.9 | 9.6% |
| Analysts Target Price | 244.9 | 9.6% |
| ValueRay Target Price | 267.4 | 19.7% |
ABBV Fundamental Data Overview February 07, 2026
P/E Forward = 15.456
P/S = 6.3292
P/B = 50.4573
P/EG = 0.3885
Revenue TTM = 61.16b USD
EBIT TTM = 9.43b USD
EBITDA TTM = 28.29b USD
Long Term Debt = 62.97b USD (from longTermDebt, two quarters ago)
Short Term Debt = 5.77b USD (from shortTermDebt, two quarters ago)
Debt = 68.74b USD (from shortLongTermDebtTotal, two quarters ago)
Net Debt = 68.74b USD (using Total Debt 68.74b, CCE unavailable)
Enterprise Value = 455.84b USD (387.09b + Debt 68.74b - (null CCE))
Interest Coverage Ratio = 3.33 (Ebit TTM 9.43b / Interest Expense TTM 2.83b)
EV/FCF = 33.00x (Enterprise Value 455.84b / FCF TTM 13.81b)
FCF Yield = 3.03% (FCF TTM 13.81b / Enterprise Value 455.84b)
FCF Margin = 22.58% (FCF TTM 13.81b / Revenue TTM 61.16b)
Net Margin = 6.91% (Net Income TTM 4.23b / Revenue TTM 61.16b)
Gross Margin = 73.34% ((Revenue TTM 61.16b - Cost of Revenue TTM 16.31b) / Revenue TTM)
Gross Margin QoQ = 84.02% (prev 66.38%)
Tobins Q-Ratio = 3.40 (Enterprise Value 455.84b / Total Assets 133.90b)
Interest Expense / Debt = 0.95% (Interest Expense 655.0m / Debt 68.74b)
Taxrate = 31.97% (853.0m / 2.67b)
NOPAT = 6.42b (EBIT 9.43b * (1 - 31.97%))
Current Ratio = 0.72 (Total Current Assets 28.54b / Total Current Liabilities 39.39b)
Debt / Equity = -26.02 (negative equity) (Debt 68.74b / totalStockholderEquity, two quarters ago -2.64b)
Debt / EBITDA = 2.43 (Net Debt 68.74b / EBITDA 28.29b)
Debt / FCF = 4.98 (Net Debt 68.74b / FCF TTM 13.81b)
Total Stockholder Equity = 480.0m (last 4 quarters mean from totalStockholderEquity)
RoA = 3.14% (Net Income 4.23b / Total Assets 133.90b)
RoE = 880.4% (Net Income TTM 4.23b / Total Stockholder Equity 480.0m)
RoCE = 14.86% (EBIT 9.43b / Capital Employed (Equity 480.0m + L.T.Debt 62.97b))
RoIC = 9.27% (NOPAT 6.42b / Invested Capital 69.24b)
WACC = 6.50% (E(387.09b)/V(455.84b) * Re(7.54%) + D(68.74b)/V(455.84b) * Rd(0.95%) * (1-Tc(0.32)))
Discount Rate = 7.54% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 100.0 | Cagr: 0.06%
[DCF Debug] Terminal Value 83.72% ; FCFF base≈15.42b ; Y1≈15.21b ; Y5≈15.68b
Fair Price DCF = 182.1 (EV 390.58b - Net Debt 68.74b = Equity 321.84b / Shares 1.77b; r=6.50% [WACC]; 5y FCF grow -2.17% → 2.90% )
EPS Correlation: -63.83 | EPS CAGR: -4.65% | SUE: -1.23 | # QB: 0
Revenue Correlation: 42.75 | Revenue CAGR: 5.62% | SUE: 0.45 | # QB: 0
EPS next Quarter (2026-03-31): EPS=3.03 | Chg30d=-0.085 | Revisions Net=+1 | Analysts=12
EPS current Year (2026-12-31): EPS=14.48 | Chg30d=+0.226 | Revisions Net=+0 | Growth EPS=+44.8% | Growth Revenue=+9.9%
EPS next Year (2027-12-31): EPS=15.90 | Chg30d=+0.058 | Revisions Net=-4 | Growth EPS=+9.8% | Growth Revenue=+7.4%